Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22793158 | 0.65 | EGFR (0.33) | — | |
| SCHEMBL22792573 | 0.64 | — | — | |
| SCHEMBL26596949 | 0.63 | — | — | |
| SCHEMBL2607564 | 0.59 | CA2 (0.41) | — | |
| SCHEMBL19968210 | 0.59 | — | — | |
| SCHEMBL7812939 | 0.58 | HTR2C (0.40) | DRD1 | |
| SCHEMBL19602920 | 0.58 | MAOA (0.34) | DRD1 | |
| SCHEMBL22792685 | 0.57 | KDM1A (0.35) | — | |
| SCHEMBL22430218 | 0.57 | DYRK1A (0.30) | — | |
| SCHEMBL2265534 | 0.57 | KCNA3 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988466-B2 | Heterocyclic derivatives useful as SHP2 inhibitors | PTPRJ, PTPN5, PTPN1 | DRD1 4802/4885 |
| US-20200392128-A1 | NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS | PTPN5, PTPN1, PTPRJ | DRD1 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.